<DOC>
	<DOCNO>NCT00384215</DOCNO>
	<brief_summary>This trial explore various advantage possible disadvantage pioglitazone insulin glargine add monotherapy . Glycemic control , hypoglycemia , weight , lipid profile , quality life cost study give comprehensive set data may help future treatment decision .</brief_summary>
	<brief_title>Insulin Glargine rDNA Origin Injection v Pioglitazone add-on Therapy Patients Failing Monotherapy With Sulfonylurea Metformin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>The following information clinical trial provide information purpose allow patient physician initial discussion trial . This information intend complete information trial , contain consideration may relevant potential participation trial , replace advice personal physician health professional . INCLUSION CRITERIA : 1 . Diagnosis type 2 diabetes mellitus least six month 2 . Continuous treatment least 1g metformin half maximally label dose SU daily least three month 3 . HbA1c &gt; /= 8 % &lt; /= 12 % , inclusive , measure screen week 4 . Willingness accept , demonstrate ability inject insulin glargine therapy 5 . Demonstrated ability willingness perform SMBG use plasmareferenced glucose meter least twice day 6 . Ability understand willingness adhere compliant study protocol EXCLUSION CRITERIA : 1 . Stroke , myocardial infarction ( MI ) , coronary artery bypass graft ( CABG ) , percutaneous transluminal coronary angioplasty ( PTCA ) angina pectoris within last 12 month 2 . Congestive heart failure require pharmacological treatment 3 . Impaired renal function , show limited serum creatinine &gt; /= 1.5 mg/dl ( 133µmol/L ) male , &gt; /= 1.4 mg/dl ( 124 µmol/L ) females 4 . Treatment nonselective betablockers ( include ocular ) 5 . Acute infection 6 . History presence sign significant peripheral edema 7 . Acute chronic history metabolic acidosis , include diabetic ketoacidosis 8 . Planned radiological examination require administration contrast agent 9 . Clinical evidence active liver disease , serum ALT 2.5 time upper limit normal range 10 . History hypoglycemia unawareness 11 . Pregnant breastfeeding female 12 . Failure use adequate contraception ( woman current reproductive potential ) 13 . BMI &lt; 25 kg/ ( ) ( ) 14 . Treatment systemic steroid large dos inhale steroid 15 . Treatment diabetes medication medication require study 16 . Use investigational drug within previous month 17 . Known hypersensitivity insulin glargine , pioglitazone component insulin glargine pioglitazone 18 . Any malignancy within last five year , except adequately treat basal cell carcinoma adequately treat cervical carcinoma situ . 19 . Current addiction alcohol abuse history substance alcohol abuse within two year 20 . Diagnosis dementia 21 . Any disease condition opinion investigator and/or sponsor may interfere completion study interpretation study result 22 . Inability comply study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>